Literature DB >> 15306753

Protein-binding oligonucleotides: the next frontier in antithrombotic therapy.

Richard C Becker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15306753     DOI： 10.1023/B:THRO.0000037673.15166.38

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  10 in total

1.  Blocking the initiation of coagulation by RNA aptamers to factor VIIa.

Authors:  C P Rusconi; A Yeh; H K Lyerly; J H Lawson; B A Sullenger
Journal:  Thromb Haemost       Date:  2000-11       Impact factor: 5.249

2.  Developing aptamers into therapeutics.

Authors:  R R White; B A Sullenger; C P Rusconi
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

3.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.

Authors:  C Tuerk; L Gold
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

4.  Selection of single-stranded DNA molecules that bind and inhibit human thrombin.

Authors:  L C Bock; L C Griffin; J A Latham; E H Vermaas; J J Toole
Journal:  Nature       Date:  1992-02-06       Impact factor: 49.962

5.  In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits.

Authors:  L C Griffin; G F Tidmarsh; L C Bock; J J Toole; L L Leung
Journal:  Blood       Date:  1993-06-15       Impact factor: 22.113

6.  A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation.

Authors:  W X Li; A V Kaplan; G W Grant; J J Toole; L L Leung
Journal:  Blood       Date:  1994-02-01       Impact factor: 22.113

7.  Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance.

Authors:  L Beigelman; J A McSwiggen; K G Draper; C Gonzalez; K Jensen; A M Karpeisky; A S Modak; J Matulic-Adamic; A B DiRenzo; P Haeberli
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

8.  Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes.

Authors:  W A Pieken; D B Olsen; F Benseler; H Aurup; F Eckstein
Journal:  Science       Date:  1991-07-19       Impact factor: 47.728

9.  Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass.

Authors:  A DeAnda; S E Coutre; M R Moon; C M Vial; L C Griffin; V S Law; M Komeda; L L Leung; D C Miller
Journal:  Ann Thorac Surg       Date:  1994-08       Impact factor: 4.330

10.  RNA aptamers as reversible antagonists of coagulation factor IXa.

Authors:  Christopher P Rusconi; Elizabeth Scardino; Juliana Layzer; George A Pitoc; Thomas L Ortel; Dougald Monroe; Bruce A Sullenger
Journal:  Nature       Date:  2002-09-05       Impact factor: 49.962
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.